Spots Global Cancer Trial Database for urothelial carcinoma bladder
Every month we try and update this database with for urothelial carcinoma bladder cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase Ib of L-NMMA and Pembrolizumab | NCT03236935 | Non-Small Cell ... Malignant Melan... Head and Neck S... Classical Hodgk... Urothelial Carc... DNA Repair-Defi... | L-NMMA Pembrolizumab | 18 Years - | The Methodist Hospital Research Institute | |
| Urothelial Cancer Tumor Bio-markers and Physical-spectroscopic Characteristic | NCT04770974 | Urothelial Carc... Bladder Cancer Urothelial Neop... Urothelial Carc... Urothelial Carc... | Biomarkers and ... | 18 Years - | University of Florence | |
| Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer | NCT05241340 | Urothelial Carc... | Sasanlimab Stereotactic Bo... Radical Cystect... | 18 Years - | The Methodist Hospital Research Institute | |
| A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer | NCT05243550 | Bladder Cancer Urothelial Carc... Urothelial Carc... | UGN-102 | 18 Years - | UroGen Pharma Ltd. | |
| En Bloc Bladder Tumor Resection: Prospective Randomized Study | NCT04712201 | Urothelial Carc... Bladder Cancer | En bloc transur... Conventional TU... | 18 Years - | Fundacio Puigvert | |
| En Bloc Bladder Tumor Resection: Prospective Randomized Study | NCT04712201 | Urothelial Carc... Bladder Cancer | En bloc transur... Conventional TU... | 18 Years - | Fundacio Puigvert | |
| Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) | NCT05037279 | Bladder Cancer Bladder Cancer ... Neoplasm Recurr... Urothelial Carc... Urothelial Carc... Non-Invasive Bl... | Bacillus Calmet... Bacillus Calmet... | 18 Years - | Verity Pharmaceuticals Inc. | |
| Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) | NCT05136898 | Bladder Cancer Urothelial Carc... Urothelial Carc... | UGN-102 | 18 Years - | UroGen Pharma Ltd. | |
| A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer | NCT05243550 | Bladder Cancer Urothelial Carc... Urothelial Carc... | UGN-102 | 18 Years - | UroGen Pharma Ltd. | |
| IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC | NCT05077709 | Lung Cancer Non... Head and Neck S... Urothelial Carc... | IO102-IO103 in ... | 18 Years - | IO Biotech | |
| A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer | NCT03558503 | Bladder Cancer Urothelial Carc... Urothelial Carc... | UGN-102 | 18 Years - | UroGen Pharma Ltd. | |
| Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer | NCT04386746 | Urothelial Carc... Bladder Cancer | Gemcitabine Docetaxel | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Renal Retention in High Grade Upper Tract Urothelial Cancer | NCT05656235 | High Grade Urot... Bladder Cancer Urothelial Carc... | Enfortumab vedo... Pembrolizumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer | NCT05312671 | Small Cell Neur... Bladder Cancer Urothelial Carc... | Atezolizumab Carboplatin Cisplatin Etoposide Cystectomy | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Renal Retention in High Grade Upper Tract Urothelial Cancer | NCT05656235 | High Grade Urot... Bladder Cancer Urothelial Carc... | Enfortumab vedo... Pembrolizumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Phase 3 Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer | NCT04688931 | Bladder Cancer Urothelial Carc... Urothelial Carc... | UGN-102 TURBT | 18 Years - | UroGen Pharma Ltd. | |
| Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) | NCT05037279 | Bladder Cancer Bladder Cancer ... Neoplasm Recurr... Urothelial Carc... Urothelial Carc... Non-Invasive Bl... | Bacillus Calmet... Bacillus Calmet... | 18 Years - | Verity Pharmaceuticals Inc. | |
| A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer | NCT03558503 | Bladder Cancer Urothelial Carc... Urothelial Carc... | UGN-102 | 18 Years - | UroGen Pharma Ltd. | |
| Bladder Cancer Adjuvant Radiotherapy Trial | NCT02951325 | Bladder Cancer Urothelial Carc... | Adjuvant RT | 18 Years - | Tata Memorial Centre | |
| Adjuvant Radiotherapy Versus Observation After Radical Cystectomy in High Risk Urothelial Bladder Cancer | NCT04740866 | High-Risk Cance... Urothelial Carc... | Adjuvant Radiot... | 18 Years - | Cairo University | |
| A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer | NCT06331299 | Bladder Cancer Urothelial Carc... Urothelial Carc... | UGN-103 | 18 Years - | UroGen Pharma Ltd. | |
| A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) | NCT05375903 | Non-muscle Inva... NMIBC Carcinoma in Si... Bladder Cancer Urothelial Carc... Urothelial Carc... | UGN-301 UGN-201 Gemcitabine | 18 Years - | UroGen Pharma Ltd. | |
| Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer | NCT04386746 | Urothelial Carc... Bladder Cancer | Gemcitabine Docetaxel | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer | NCT05241340 | Urothelial Carc... | Sasanlimab Stereotactic Bo... Radical Cystect... | 18 Years - | The Methodist Hospital Research Institute | |
| A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer | NCT05243550 | Bladder Cancer Urothelial Carc... Urothelial Carc... | UGN-102 | 18 Years - | UroGen Pharma Ltd. | |
| Adjuvant Radiotherapy Versus Observation After Radical Cystectomy in High Risk Urothelial Bladder Cancer | NCT04740866 | High-Risk Cance... Urothelial Carc... | Adjuvant Radiot... | 18 Years - | Cairo University | |
| En Bloc Bladder Tumor Resection: Prospective Randomized Study | NCT04712201 | Urothelial Carc... Bladder Cancer | En bloc transur... Conventional TU... | 18 Years - | Fundacio Puigvert | |
| Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer | NCT05401279 | Urothelial Carc... PD-1 Inhibitor | Tislelizumab Gemcitabine Cisplatin | 18 Years - 75 Years | RenJi Hospital | |
| Bladder Cancer Adjuvant Radiotherapy Trial | NCT02951325 | Bladder Cancer Urothelial Carc... | Adjuvant RT | 18 Years - | Tata Memorial Centre | |
| Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer | NCT04386746 | Urothelial Carc... Bladder Cancer | Gemcitabine Docetaxel | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) | NCT05375903 | Non-muscle Inva... NMIBC Carcinoma in Si... Bladder Cancer Urothelial Carc... Urothelial Carc... | UGN-301 UGN-201 Gemcitabine | 18 Years - | UroGen Pharma Ltd. | |
| Phase Ib of L-NMMA and Pembrolizumab | NCT03236935 | Non-Small Cell ... Malignant Melan... Head and Neck S... Classical Hodgk... Urothelial Carc... DNA Repair-Defi... | L-NMMA Pembrolizumab | 18 Years - | The Methodist Hospital Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
